From Evidence to Effectiveness: Implications of the Randomized Trial to Prevent Vascular Events in HIV Study for People With HIV in Low- and Middle-Income Settings.

Autor:	Manne-Goehler J; Division of Infectious Diseases, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA., Ali MK; Emory Global Diabetes Research Center of Woodruff Health Sciences Center and Emory University, Atlanta, Georgia, USA.; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.; Department of Family and Preventive Medicine, School of Medicine, Emory University, Georgia, USA., Flood D; Department of Medicine, University of Michigan, Ann Arbor, Michigan, USA., Marconi VC; Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA.; Division of Infectious Diseases, Emory University School of Medicine, Emory University, Atlanta, Georgia, USA., Venter WDF; Wits Ezintsha, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa., Siedner MJ; Medical Practice Evaluation Center, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Division of Infectious Diseases, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA.; Clinical Research Department, Africa Health Research Institute, KwaZulu-Natal, South Africa.
Jazyk:	angličtina
Zdroj:	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America [Clin Infect Dis] 2024 Jun 14; Vol. 78 (6), pp. 1401-1402.
DOI:	10.1093/cid/ciad702
Abstrakt:	The Randomized Trial to Prevent Vascular Events in HIV (REPRIEVE) study found a 35% reduction in major adverse cardiovascular events for people with human immunodeficiency virus who received daily pitavastatin. However, how this evidence will change practice is far from certain. Here, we outline evidence gaps and political and healthcare delivery challenges that will need to be addressed for REPRIEVE to offer public health benefits in low- and middle-income countries. Competing Interests: Potential conflicts of interest. J. M.-G. reports grants or contracts from GSK Pharmaceuticals and Regeneron Pharmaceuticals and consulting fees from the World Health Organization (WHO). V. C. M. reports grants or contracts from Gilead for ACTT2, ACTT3, and ACTT4, from ViiV for DISCO and ASPIRE, and from CDC/NIH/VA for other studies; participation on a data and safety monitoring board or advisory board for IL-1b inhibitor study, CLEAR HIV, VB201, Outsmart, and ECLIPSE; and a role as study section chair for NIH. M. K. A. reports personal fees outside the scope of this work from Eli Lilly. D. F. reports consulting fees (to institution) as a diabetes consultant for the WHO; career development funding on implementation science for cardiovascular disease prevention (award K23HL161271) from NIH; and service as an unpaid staff physician for the Maya Health Alliance and GlucoSalud (nongovernmental health organizations in Guatemala). W. D. F. V. reports grants or contracts unrelated to this work from the Bill and Melinda Gates Foundation, US Agency for International Development, Unitaid, SA Medical Research Council, Foundation for Innovative New Diagnostics, Children's Investment Fund Foundation, Gilead, ViiV, Mylan, Merck, Adcock-Ingram, Aspen, Abbott, Roche, Johnson & Johnson, Sanofi, Virology Education, SA HIV Clinicians Society, and Dira Sengwe. All other authors report no potential conflicts. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. (© The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu